The earnings call reflected a positive outlook for LeMaitre Vascular, with strong sales growth, improved margins, and successful product launches contributing to increased financial guidance. While there were some challenges, such as a catheter recall and rising operating expenses, the company demonstrated resilience and strategic positioning in expanding its international market presence.

Company Guidance

During the Q2 2025 earnings call, LeMaitre Vascular reported a strong quarter with sales up 15% and EPS increasing by 16%. The gross margin stood at 70%, and operating income rose by 12% to $16.1 million, resulting in an operating margin of 25%. International sales were robust, with EMEA growing by 23%, and the Artegraft launch exceeding expectations with sales of $420,000 in Q2. LeMaitre raised its full-year revenue guidance to $251 million, forecasting 15% organic growth, a gross margin of 69.7%, and operating income of $60.9 million. The company ended Q2 with $319.5 million in cash and securities, reporting record cash from operations at $20.3 million. Their sales force expanded to 164 reps, contributing to the healthy sales growth observed across global markets.

Strong Financial Performance

Sales increased by 15%, gross margin reached 70%, and EPS rose by 16%. Full-year guidance for sales, gross margin, operating income, and EPS has been increased.

Product Segment Growth

Catheters sales increased by 27%, grafts by 19%, while Valvulotomes and Chunnt both grew by 13%.

Geographical Sales Growth

EMEA sales grew by 23%, Americas by 12%, and APAC by 12%.

Successful International Artegraft Launch

International Artegraft sales exceeded expectations, reaching $420,000 in Q2, up from $185,000 in Q1. Full-year sales are expected to surpass $2 million.

Strong Cash Flow and Financial Position

Cash from operations generated a record $20.3 million in Q2. The company ended Q2 with $319.5 million in cash and securities, an increase of $17 million.

Positive Regulatory Developments

Progress made in international regulatory approvals for Artegraft, with expected approvals in Canada, Korea, and Singapore in 2026.

Increased Full Year Guidance

Guidance raised to $251 million in revenue and 15% organic growth, with gross margin anticipated at 69.7% and operating income at $60.9 million.

Lemaitre Vascular (LMAT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LMAT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.57 / -	0.49	―	―	―
Aug 05, 2025	2025 (Q2)	0.57 / 0.60	0.52	15.38% (+0.08)	―
May 01, 2025	2025 (Q1)	0.50 / 0.48	0.44	9.09% (+0.04)	―
Feb 27, 2025	2024 (Q4)	0.49 / 0.49	0.38	28.95% (+0.11)
Oct 31, 2024	2024 (Q3)	0.43 / 0.49	0.33	48.48% (+0.16)
Aug 01, 2024	2024 (Q2)	0.47 / 0.52	0.36	44.44% (+0.16)
May 02, 2024	2024 (Q1)	0.39 / 0.44	0.27	62.96% (+0.17)
Feb 27, 2024	2023 (Q4)	0.36 / 0.38	0.25	52.00% (+0.13)
Nov 01, 2023	2023 (Q3)	0.31 / 0.33	0.25	32.00% (+0.08)	―
Aug 01, 2023	2023 (Q2)	0.32 / 0.36	0.16	125.00% (+0.20)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LMAT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$85.42	$93.04	+8.92%
May 01, 2025	$89.84	$78.35	-12.79%
Feb 27, 2025	$99.22	$91.21	-8.07%
Oct 31, 2024	$87.64	$94.08	+7.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lemaitre Vascular (LMAT) report earnings?

Lemaitre Vascular (LMAT) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Lemaitre Vascular (LMAT) earnings time?

Lemaitre Vascular (LMAT) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LMAT EPS forecast?

LMAT EPS forecast for the fiscal quarter 2025 (Q3) is 0.57.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing